Skip to main content

Table 1 Characteristics of reports extracted from the databases

From: Efficacy and safety of traditional Chinese medicine in the treatment of menopause-like syndrome for breast cancer survivors: a systematic review and meta-analysis

Study

Randomized method

Sample size

(E/C)

BC’s stage

Menstrual cycle

Age

Experimental group

Control

group

Duration

Outcomes

Bailing Shi, 2010;China

Random number table method

12/13

N

Post-menopausal

EG: 60.00 ± 4.84

CG: 61.78 ± 3.3

Traditional Chinese Medicine (TCM) + Aromatase inhibitor(AI) + Calcium tablet

AI+Calcium tablet

24 w

⑧

Chenlu Liang et al., 2018; China

Random number table method

42/43

I II III

Premenopausal

EG: 37.74 ± 6.6

CG: 37.16 ± 6.28

Black Cohosh+Luteinizing hormone releasing hormone analogue-α(LHRH-α)

LHRH-α

12 w

⑧⑨

Chen Nie, 2018;China

Not reported

20/20

I II

Premenopausal

EG: 41.1 ± 4.3

CG: 43.65 ± 5.36

Yiqiyangyinjiedu(YQYYJD) formula+Tamoxifen

Tamoxifen

12 w

①④⑤⑥

Chen Sun, 2009;China

Not reported

30/30

N

N

Not reported

Xiaoyaoerxian(XYEX) Decoction+Tamoxifen

Tamoxifen+Oryzanol

12 w

①⑦⑧⑨

Chen Wang et al.,2019;China

Randomized

envelop method

42/43

I II III

Premenopausal

EG: 37.74 ± 6.60

CG: 37.16 ± 6.28

Black Cohosh+LHRH-α

LHRH-α

12 w

⑧⑨⑩

Cheri L. Van Patten et al.,2002; American

Not reported

59/64

I II III

Post-menopausal

EG: 55.5 ± 6.3

CG: 54.9 ± 6.5

Soy

placebo

12 w

⑪

Chundi Gao, 2019; China

Random number table method

24/24

N

N

EG: 44.13 ± 4.875

CG: 45.25 ± 4.386

Erxian(EX) Decoction+Tamoxifen

Tamoxifen

12 w

①⑦⑧⑨⑩

Congshan Li et al., 2021;China

Random number table method

30/30

I II III

Premenopausal

EG: 44.18 ± 3.39

CG: 44.97 ± 3.17

Chaihujialonggumuli(CHJLGML) Decoction+Oryzanol

Oryzanol

12 w

①②③④⑤⑥⑦

Guilan Tan, 2014;China

simple randomization

16/16

I II III

Post-menopausal

EG: 60.36 ± 8.64

CG: 59.00 ± 4.76

Bushen(BS) formula+AI+Calcium tablet

AI+Calcium tablet

Not reported

①⑧

Haisong Lu et al., 2016;China

Random number table method

30/30

N

Premenopausal

EG: 35 ~ 50

CG: 34 ~ 50

Xiaogeng(XG) powder+Tamoxifen

Tamoxifen+Oryzanol+Vitamin B6

8 w

⑧⑨⑩

Han Xiao et al., 2019;China

Random number table method

25/25

EG:I1 5 II 11

CG:I1 7 II 10

Post-menopausal

EG: 60.8 ± 8.7

CG: 62.1 ± 9.4

Jiaweizhibaidihuang(JWZBDH) Decoction+AI+Oryzanol

AI+Oryzanol

8 w

①⑧⑨

Hongxia Li et al., 2020; China

Random number table method

47/49

EG:I1 1 II 28 III 8

CG:I1 2 II 30 III 7

Premenopausal

EG: 42.3 ± 6.5

CG: 42.5 ± 7.1

Qianyangfengsui(QYFS) pellet+Oryzanol

Oryzanol

12 w

①⑦⑧

Huifen Yang et al., 2015;China

Not reported

69/33

N

Premenopausal

Not reported

Erzhi(EZ) pill +Guizhi(GZ) Decoction

Oryzanol

12 w

⑧⑨⑩

Huifen Yang et al., 2016;China

Random number table method

69/69

EG:I 22 II 38 III 9

CG:I 19 II 39

III 11

Premenopausal

Not reported

Erzhi(EZ) pill +Guizhi(GZ) Decoction

Oryzanol

8 w

①⑧⑨⑩

Hui Liu et al., 2016;China

Not reported

34/34

EG:II 25 III

10

CG:II 33 III

12

Premenopausal

Not reported

Yiguan(YG) Decoction+LHRH-α + AI

LHRH-α + AI

12 w

⑧⑨

Hui Zhang,2018; China

Random number table method

30/30

EG:I 3 II 14 III 9 IV 4

CG:I 1 II 15 III 11 IV 3

N

Not reported

Erjialonggu(EJLG) Decoction+Endocrine therapy

Endocrine therapy+Oryzanol

2 w

①③④⑤⑥⑦⑧⑨

Jingru Song, 2019;China

Random number table method

27/28

EG:I 4 II 10 III 6 IV 7

CG:I 5 II 12 III 5 IV 6

Post-menopausal

EG: 51.44 ± 10.970

CG: 50.75 ± 12.477

Chaihujialonggumuli(CHJLGML) Decoction+AI

AI

12 w

①⑦

Juan Zhou,2020; China

Random number table method

36/36

N

N

EG: 53.00 ± 6.51

CG: 52.00 ± 5.44

Xiao yao an kun(XYAK) Decoction+Endocrine therapy

Endocrine therapy+placebo

8 w

②③④⑤⑥

Judith S. Jacobson et al.,2001; American

Random number table method

29/30

N

N

Not reported

Black Cohosh

placebo

8 w

⑨⑩⑪

Junwen Pei et al., 2019;China

Random number table method

30/30

EG:I 4 II 12 III 8 IV 6

CG: I 8 II10 III 7 IV 5

N

EG: 52.76 ± 8.0

CG: 55.66 ± 7.59

Danzhixiaoyao(DZXY) powder+Erxian(EX) Decoction+Endocrine therapy

Endocrine therapy

4 w

①⑦⑧⑨⑩

Junyuan Cai et al., 2021;China

Random number table method

30/30

N

Post-menopausal

EG: 61.2 ± 8.5

CG:61.9 ± 9.2

Fuzhengxiaoliu(FZXL) Decoction

Oryzanol+Vitamin B6

8 w

①⑧⑨⑩

Kaili Xu, 2019;China

Not reported

50/53

EG:I 20 II 30

CG:I 33 II 30

N

Not reported

Dangguiliuhuang(DGLH) Decoction+AI

AI

Not reported

â‘ 

Lan Luo et al., 2019;China

simple randomization

30/30

N

Premenopausal

EG: 44.07 ± 3.23

CG: 44.37 ± 3.08

JiaTCMibushen(JPBS) formula+Tamoxifen

Tamoxifen

4 w

①④⑤⑥⑪

Limin Zhu,2020; China

Random number table method

61/60

EG:II47 III 14

CG:II47 III13

Post-menopausal

EG: 59.43 ± 6.40

CG: 59.7 ± 6.61

Ruyanning(RYN) formula+AI

AI

8 w

â‘ 

Lina Sheng, 2014;China

Not reported

23/20

N

N

Not reported

Yangshenshugan(YSSG) Decoction+Endocrine therapy+Oryzanol+Vitamin B1

Endocrine therapy+Oryzanol+Vitamin B1

3 w

①⑦⑧⑨

Liujing Ou, 2018;China

Not reported

50/50

N

Post-menopausal

EG: 61.73 ± 5.9

CG: 61.66 ± 5.87

Bushenquyu (BSQY) formula+AI

AI

24 w

①⑦⑧⑪

Ming Feng et al.,2021

Interactive response

technology

45/45

EG:I 15 II 30

CG:I 18 II 27

N

EG: 53.8 ± 7.04

CG:51.85 ± 7.84

Sanhuang(SH) Decoction

None

24w

â‘ 

Rongfei Jiang, 2021; China

Not reported

29/29

N

N

EG: 51.89 ± 9.97

CG: 55.89 ± 10.58

Chaihujialonggumuli(CHJLGML) Decoction+Endocrine therapy

Endocrine therapy

8 w

â‘ 

Rui Qiang, 2020;China

Random number table method

36/36

N

Post-menopausal

EG: 64.3 ± 5.5

CG: 63.7 ± 5.9

Banxiaxiexin(BXXX) Decoction+Endocrine therapy

Endocrine therapy

2 w

⑧⑨⑩

Ruiqing Sui, 2019;China

Not reported

29/30

N

Post-menopausal

Not reported

Zishuihanmu(ZSHM) formula+Endocrine therapy

Endocrine therapy

8 w

①②③⑥

Suzhen Lin et al., 2016;China

Not reported

34/34

N

Premenopausal

Not reported

Yiguan(YG) Decoction+Tamoxifen

Tamoxifen

12 w

②⑤

Ting Li et al., 2020;China

Not reported

36/36

N

N

EG: 51.88 ± 10.10

CG: 47.69 ± 10.73

Xiaoyaoankun(XYAK) Decoction+Endocrine therapy

Endocrine therapy+Placebo

8 w

②③④⑤⑥⑧⑨

Weikang Zhu,2020; China

Not reported

40/40

N

Post-menopausal

EG: 64.25 ± 5.67

CG: 60.28 ± 5.88

Bushenshugan(BSSG) formula+Calcium tablet

Calcium tablet

24 w

①⑦⑧⑨⑩⑪

Xiaoling Wang, 2018;China

Not reported

30/30

N

Premenopausal

EG: 40.66 ± 6.87

CG: 40.73 ± 6.9

TCM + Oryzanol

Oryzanol

12 w

①⑦⑧⑨⑩⑪

Xiaomei Wu et al., 2021;

China

Random number table method

39/39

EG:I 5 II 14 III 13 IV 7

CG:I 6 II 14 III 13 IV 5

N

EG: 53.44 ± 5.49

CG: 53.38 ± 5.74

TCM + Oryzanol+Tamoxifen+Vitamin B1

Oryzanol+Tamoxifen+Vitamin B1

12w

⑧⑨⑩

Xiaozhen Liang, 2011; China

Not reported

40/40

N

Premenopausal

EG: 47.5

CG: 47

Liuweidihuang(LWDH) Decoction+Oryzanol

Oryzanol

8 w

⑦

Yang Fu, 2016; China

Random number table method

50/50

EG:I ~ II 26

III ~ IV 24

CG:I ~ II24

III ~ IV 26

N

EG: 45.1 ± 12.2

CG: 42.9 ± 13.8

Heixiaoyao(HXY) Powder+Shensiwei(SSW) Decoction+Tamoxifen

Tamoxifen+Oryzanol+Vitamin B1 + Vitamin B6

16 w

①⑧⑨

Yemei Li et al., 2022; China

Not reported

25/25

EG:I 7 II11 III 7

CG:I 8 II10 III 7

N

EG: 53.76 ± 8.86

CG: 54.96 ± 8.55

Jiaweifangjidihuang(JWFJDH) Decoction

Alprazolam

2 w

â‘ 

Yining Song et al., 2014;China

Not reported

60/60

N

N

Not reported

Black Cohosh

placebo

12 w

â‘ 

Zhihui Tao et al., 2020;China

Random number table method

30/30

EG:I ~ II 24 III ~ IV 6

CG:I ~ II 24 III ~ IV 26

N

EG: 50.263 ± 5.230

CG:51.566 ± 7.0353

Yishenkangai(YSKA) formula+Endocrine therapy

Endocrine therapy+Oryzanol

8 w

①⑦

Zhipei Han et al., 2021; China

Not reported

40/40

EG:I 1 II 20 III 15 IV 4

CG:I 2 II 14 III 18 IV 6

Post-menopausal

EG: 58.93 ± 7.15

CG: 58.80 ± 7.13

Ruyanning(RYN) formula+AI

AI

8 w

①⑧⑨⑩

Ziyi Yan, 2021;China

Random number table method

28/28

EG:I 4 II 19 III 5

CG:I 8 II 16 III 4

N

Not reported

Qingxinzishen(QXZS) Decoction+Endocrine therapy

Endocrine therapy

12 w

①②③④⑥⑧⑨

  1. ①: Total of KMI; ②: Hot flashes and night sweats in KMI; ③: Paraesthesia in KMI; ④: Osteoarthralgia in KMI; ⑤: Anxiety in KMI; ⑥: Insomnia in KMI; ⑦: objective response rate (ORR); ⑧: E2; ⑨: FSH; ⑩: LH; ⑪: Adverse Events (AEs). CG control group, EG experimental group, N not reported